Abstract
The effect of equivalent hypolipidaemic doses of cholestyramine (8 g) or colestipol (10 g) on the plasma concentrations of propranolol and 4'-hydroxypropranolol was studied in 12 normal volunteers following the oral administration of 120 mg of normal release propranolol tablets. When two doses of either cholestyramine or colestipol were administered prior to the propranolol, the peak plasma concentrations and area under the curve for both propranolol and the metabolite 4'-hydroxypropranolol were reduced significantly (P less than 0.05). We conclude that the drug interaction between cholestyramine or colestipol and propranolol leads to significant reductions in plasma concentrations of propranolol and 4'-hydroxypropranolol which may cause a clinically diminished effect for a given dosage. Therefore, patients should be observed when either of these resins are added to or deleted from a therapeutic regimen.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Caldwell J. H., Greenberger N. J. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication. J Clin Invest. 1971 Dec;50(12):2626–2637. doi: 10.1172/JCI106763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Charles B. G., Renshaw P. J., Kay J. J., Ravenscroft P. J. Effect of metoclopramide on the bioavailability of long-acting propranolol. Br J Clin Pharmacol. 1981 May;11(5):517–518. doi: 10.1111/j.1365-2125.1981.tb01159.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cotham R. H., Shand D. Spuriously low plasma propranolol concentrations resulting from blood collection methods. Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):535–538. doi: 10.1002/cpt1975185part1535. [DOI] [PubMed] [Google Scholar]
- Gallo D. G., Bailey K. R., Sheffner A. L. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med. 1965 Oct;120(1):60–65. doi: 10.3181/00379727-120-30443. [DOI] [PubMed] [Google Scholar]
- Grabowski B. S., Cady W. J., Young W. W., Emery J. F. Effects of acute alcohol administration on propranolol absorption. Int J Clin Pharmacol Ther Toxicol. 1980 Jul;18(7):317–319. [PubMed] [Google Scholar]
- Gyselinck P., Remon J. P., Van Severen R., Braeckman P. An improved extraction procedure for the liquid chromatographic determination of propranolol and 4-hydroxypropranolol in plasma. Br J Clin Pharmacol. 1980 Oct;10(4):406–408. doi: 10.1111/j.1365-2125.1980.tb01779.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lüllmann H., Wehling M. The binding of drugs to different polar lipids in vitro. Biochem Pharmacol. 1979 Dec 1;28(23):3409–3415. doi: 10.1016/0006-2952(79)90080-7. [DOI] [PubMed] [Google Scholar]
- Melander A., Danielson K., Scherstén B., Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther. 1977 Jul;22(1):108–112. doi: 10.1002/cpt1977221108. [DOI] [PubMed] [Google Scholar]
- Routledge P. A., Shand D. G. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73–90. doi: 10.2165/00003088-197904020-00001. [DOI] [PubMed] [Google Scholar]
- Schneck D. W., Pritchard J. F., Hayes A. H., Jr Measurement of propranolol, 4-hydroxypropranolol and propranolol glycol in human plasma. Res Commun Chem Pathol Pharmacol. 1979 Apr;24(1):3–12. [PubMed] [Google Scholar]
- Wood A. J., Feely J. Pharmacokinetic drug interactions with propranolol. Clin Pharmacokinet. 1983 May-Jun;8(3):253–262. doi: 10.2165/00003088-198308030-00004. [DOI] [PubMed] [Google Scholar]